Details for Patent: 11,376,237
✉ Email this page to a colleague
Which drugs does patent 11,376,237 protect, and when does it expire?
Patent 11,376,237 protects VABOMERE and is included in one NDA.
This patent has fourteen patent family members in fourteen countries.
Summary for Patent: 11,376,237
| Title: | Methods of treating bacterial infections |
| Abstract: | Methods of treating bacterial infection in immunocompromised subjects and subjects with one or more underlying malignancies include administering a combination of meropenem and vaborbactam to the subject. Suitable subjects to be treated can include a subject with a history of ongoing leukemia or lymphoma, a subject that has had an organ transplant, stem cell transplant, bone marrow transplant, or splenectomy, a subject receiving immunosuppressive medications, a subject receiving bone marrow ablative chemotherapy, a subject with neutropenia and subject suffering from or having suffered from a malignancy. |
| Inventor(s): | Alexander; Elizabeth (Maplewood, NJ), Loutit; Jeffrey S. (Los Altos, CA), Dudley; Michael N. (San Diego, CA) |
| Assignee: | MELINTA SUBSIDIARY CORP. (Morristown, NJ) |
| Application Number: | 16/753,288 |
|
Patent Claim Types: see list of patent claims | Use; Device; |
Drugs Protected by US Patent 11,376,237
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rempex | VABOMERE | meropenem; vaborbactam | POWDER;INTRAVENOUS | 209776-001 | Aug 29, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI,KLEBSIELLA PNEUMONIA,ENTEROBACTER CLOACAE SPECIES COMPLEX WITH MEROPENEM & VABORBACTAM AS SPECIFIED | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 11,376,237
| PCT Information | |||
| PCT Filed | October 01, 2018 | PCT Application Number: | PCT/US2018/053772 |
| PCT Publication Date: | April 11, 2019 | PCT Publication Number: | WO2019/070591 |
International Family Members for US Patent 11,376,237
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2018345317 | ⤷ Try a Trial | |||
| Brazil | 112020006658 | ⤷ Try a Trial | |||
| Canada | 3078238 | ⤷ Try a Trial | |||
| Chile | 2020000892 | ⤷ Try a Trial | |||
| China | 111432821 | ⤷ Try a Trial | |||
| European Patent Office | 3691652 | ⤷ Try a Trial | |||
| Jordan | P20200075 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
